Comparison of patients with and without transplant
| Characteristic . | Overall, N = 81 . | With transplant . | Without transplant, n = 23 . | P value∗ . | |
|---|---|---|---|---|---|
| Allogeneic, n = 47 . | Autologous, n = 11 . | ||||
| Time to first relapse (mo) | .61 | ||||
| Median (IQR) | 8.9 (6- 15) | 9 (6-12) | 9 (7-16) | 10 (6-24) | |
| Range | 3-132 | 3-132 | 5-129 | 3-97 | |
| Time to first relapse <1 or >1 y | .14 | ||||
| Relapsed in <1 y, n (%) | 53 (65) | 35 (74) | 6 (55) | 12 (52) | |
| Relapsed in >1 y, n (%) | 28 (35) | 12 (26) | 5 (45) | 11 (48) | |
| Stage at first relapse, n (%) | .60 | ||||
| I | 7 (9) | 3 (6) | 1 (9) | 3 (13) | |
| II | 12 (15) | 5 (11) | 2 (18) | 5 (22) | |
| III | 31 (38) | 20 (43) | 5 (45) | 6 (26) | |
| IV | 27 (33) | 18 (38) | 3 (27) | 6 (26) | |
| Unknown | 4 (5) | 1 (2) | 0 | 3 (13) | |
| CNS and BM involvement | .63 | ||||
| CNS positive, BM negative, n (%) | 3 (4) | 1 (2) | 1 (10) | 1 (4) | |
| BM positive, CNS negative, n (%) | 21 (26) | 14 (30) | 2 (18) | 5 (22) | |
| Both CNS and BM positive, n (%) | 3 (4) | 3 (6) | 0 (0) | 0 (0) | |
| Both CNS and BM negative, n (%) | 54 (66) | 29 (62) | 9 (82) | 17 (74) | |
| First reinduction regimen, n (%) | .26 | ||||
| ALK inhibitor | 37 (46) | 21 (45) | 5 (45) | 11 (48) | |
| Brentuximab | 19 (23) | 14 (30) | 0 (0) | 5 (22) | |
| Chemotherapy | 12 (15) | 4 (8) | 4 (36) | 4 (17) | |
| Chemotherapy + targeted therapy | 9 (11) | 5 (11) | 2 (18) | 2 (9) | |
| Vinblastine | 4 (5) | 3 (6) | 0 (0) | 1 (4) | |
| Lines of relapse therapy, n (%) | .49 | ||||
| 1 | 50 (62) | 25 (53) | 7 (64) | 18 (79) | |
| 2 | 16 (20) | 11 (24) | 2 (18) | 3 (13) | |
| 3 | 10 (12) | 8 (17) | 1 (9) | 1 (4) | |
| 4 | 3 (4) | 1 (2) | 1 (9) | 1 (4) | |
| 5 | 2 (2) | 2 (4) | 0 (0) | 0 (0) | |
| Second relapse, n (%) | 18 (22) | 9 (19) | 4 (36) | 5 (22) | .48 |
| Treatment outcome, n (%) | .005 | ||||
| Alive off treatment | 51 (63) | 36 (76) | 7 (64) | 8 (35) | |
| Alive on treatment | 19 (23) | 5 (11) | 3 (27) | 11 (48) | |
| Dead | 11 (14) | 6 (13) | 1 (9) | 4 (17) | |
| Death, n (%) | .52 | ||||
| Death due to progression of ALCL | 5 (6) | 2 (4) | 0 (0) | 3 (13) | |
| Death due to treatment toxicity | 4 (5) | 3 (7) | 1 (9) | 0 (0) | |
| Death due to other causes | 2 (3) | 1 (2) | 0 (0) | 1 (4) | |
| Characteristic . | Overall, N = 81 . | With transplant . | Without transplant, n = 23 . | P value∗ . | |
|---|---|---|---|---|---|
| Allogeneic, n = 47 . | Autologous, n = 11 . | ||||
| Time to first relapse (mo) | .61 | ||||
| Median (IQR) | 8.9 (6- 15) | 9 (6-12) | 9 (7-16) | 10 (6-24) | |
| Range | 3-132 | 3-132 | 5-129 | 3-97 | |
| Time to first relapse <1 or >1 y | .14 | ||||
| Relapsed in <1 y, n (%) | 53 (65) | 35 (74) | 6 (55) | 12 (52) | |
| Relapsed in >1 y, n (%) | 28 (35) | 12 (26) | 5 (45) | 11 (48) | |
| Stage at first relapse, n (%) | .60 | ||||
| I | 7 (9) | 3 (6) | 1 (9) | 3 (13) | |
| II | 12 (15) | 5 (11) | 2 (18) | 5 (22) | |
| III | 31 (38) | 20 (43) | 5 (45) | 6 (26) | |
| IV | 27 (33) | 18 (38) | 3 (27) | 6 (26) | |
| Unknown | 4 (5) | 1 (2) | 0 | 3 (13) | |
| CNS and BM involvement | .63 | ||||
| CNS positive, BM negative, n (%) | 3 (4) | 1 (2) | 1 (10) | 1 (4) | |
| BM positive, CNS negative, n (%) | 21 (26) | 14 (30) | 2 (18) | 5 (22) | |
| Both CNS and BM positive, n (%) | 3 (4) | 3 (6) | 0 (0) | 0 (0) | |
| Both CNS and BM negative, n (%) | 54 (66) | 29 (62) | 9 (82) | 17 (74) | |
| First reinduction regimen, n (%) | .26 | ||||
| ALK inhibitor | 37 (46) | 21 (45) | 5 (45) | 11 (48) | |
| Brentuximab | 19 (23) | 14 (30) | 0 (0) | 5 (22) | |
| Chemotherapy | 12 (15) | 4 (8) | 4 (36) | 4 (17) | |
| Chemotherapy + targeted therapy | 9 (11) | 5 (11) | 2 (18) | 2 (9) | |
| Vinblastine | 4 (5) | 3 (6) | 0 (0) | 1 (4) | |
| Lines of relapse therapy, n (%) | .49 | ||||
| 1 | 50 (62) | 25 (53) | 7 (64) | 18 (79) | |
| 2 | 16 (20) | 11 (24) | 2 (18) | 3 (13) | |
| 3 | 10 (12) | 8 (17) | 1 (9) | 1 (4) | |
| 4 | 3 (4) | 1 (2) | 1 (9) | 1 (4) | |
| 5 | 2 (2) | 2 (4) | 0 (0) | 0 (0) | |
| Second relapse, n (%) | 18 (22) | 9 (19) | 4 (36) | 5 (22) | .48 |
| Treatment outcome, n (%) | .005 | ||||
| Alive off treatment | 51 (63) | 36 (76) | 7 (64) | 8 (35) | |
| Alive on treatment | 19 (23) | 5 (11) | 3 (27) | 11 (48) | |
| Dead | 11 (14) | 6 (13) | 1 (9) | 4 (17) | |
| Death, n (%) | .52 | ||||
| Death due to progression of ALCL | 5 (6) | 2 (4) | 0 (0) | 3 (13) | |
| Death due to treatment toxicity | 4 (5) | 3 (7) | 1 (9) | 0 (0) | |
| Death due to other causes | 2 (3) | 1 (2) | 0 (0) | 1 (4) | |
BM, bone marrow.
Kruskal-Wallis rank-sum test; Fisher's exact test.